Valuation: DNAPrint Genomics, Inc.

Market Cap 2.58M 2.26M 2.08M 1.92M 3.65M 246M 3.71M 24.86M 9.76M 121M 9.68M 9.47M 416M P/E 2005
-0.23x
P/E 2006 -0.27x
Enterprise Value 1.36M 1.19M 1.1M 1.02M 1.93M 130M 1.96M 13.15M 5.16M 64.08M 5.12M 5.01M 220M EV / Sales 2005
1.89x
EV / Sales 2006 1.06x
Free-Float
100%
Yield 2005 *
-
Yield 2006 -
1 year 0
Extreme 0
0
3 years 0
Extreme 0
0
5 years 0
Extreme 0
0
10 years 0
Extreme 0
0
Manager TitleAgeSince
Director of Finance/CFO - 22/12/2009
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 1.29K
+0.58%+2.06%+3.90%+10.40% 50.73B
-2.22%-1.25%+391.53%+591.38% 39.73B
-0.54%+0.39%+27.67%-3.89% 34.69B
-1.36%+0.35%+19.34%+58.83% 33.21B
+1.21%-4.58%+3.00%+37.03% 26.76B
-1.81%-1.48% - - 16.8B
+0.51%-3.47%+66.38%+125.61% 15.37B
+0.23%-0.58%+13.80%+19.56% 13.78B
-0.62%-3.09%+11.43%-29.93% 12.85B
Average -0.40%-0.75%+67.13%+101.12% 24.39B
Weighted average by Cap. -0.48%-0.23%+82.75%+126.14%

Financials

2005 2006
Net sales 1.28M 1.12M 1.03M 950K 1.8M 122M 1.83M 12.3M 4.83M 59.93M 4.79M 4.68M 206M 2.43M 2.13M 1.96M 1.81M 3.44M 232M 3.5M 23.45M 9.21M 114M 9.14M 8.94M 393M
Net income -8.72M -7.62M -7.03M -6.49M -12.32M -831M -12.53M -84.02M -32.99M -410M -32.73M -32.01M -1.41B -12.35M -10.8M -9.96M -9.2M -17.46M -1.18B -17.75M -119M -46.75M -580M -46.36M -45.36M -1.99B
Net Debt -737K -644K -594K -549K -1.04M -70.27M -1.06M -7.1M -2.79M -34.61M -2.77M -2.71M -119M -1.21M -1.06M -980K -905K -1.72M -116M -1.75M -11.71M -4.6M -57.07M -4.56M -4.46M -196M
Logo DNAPrint Genomics, Inc.
DNAPrint genomics, Inc. is a development-stage pharmaceutical company. As of March 15, 2007, the Company’s pharmacogenomics products were still in development. The Company generates revenues in its consumer, forensic and genotyping services, but these services have not resulted in the generation of significant revenues. During the year ended December 31, 2006, the Company’s revenues were from the sales of its ancestry product, AncestryByDNA and genotyping services. The Company provides services that range from sequencing and genotyping to the entire process of single nucleotide polymorphisms (SNP) discovery to large industrial customers. Contract genotyping is the process of reading a genetic sequence and identifying differences in the sequence letters. This information helps researchers understand how human differences are expressed at the gene level.
Employees
25
Date Price Change Volume
  1. Stock Market
  2. Stocks
  3. DNAG Stock